Organovo Holdings, Inc. (ONVO) News

Organovo Holdings, Inc. (ONVO): $2.47

-0.32 (-11.47%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter ONVO News Items

ONVO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest ONVO News From Around the Web

Below are the latest news stories about Organovo Holdings Inc that investors may wish to consider to help them evaluate ONVO as an investment opportunity.

Why Organovo Holdings, Inc. Stock Soared 49.7% This Week

The company''s licensing agreement with a Swedish company means an infusion of some much-needed cash for Organovo.

The Motley Fool | March 3, 2022

UPDATE -- Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents

SAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), and BICO (OTCPK: CLLKF, Nasdaq Stockholm: BICO.ST) announced they have reached agreement on a broad license for BICO and its affiliate companies to Organovo’s foundational patent portfolio in 3D bioprinting. Founded in 2016, BICO (formerly Cellink) is the leading bio convergence company in the world. Cellink continues to operate as a wholly owned division of BICO. Organovo exclusively licensed early bioprinting

Yahoo | March 1, 2022

Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents

SAN DIEGO, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO ), and BICO today announced they have reached agreement on a broad license for BICO and its affiliate companies to Organovo''s foundational patent portfolio in 3D bioprinting. Founded in 2016, BICO (formerly Cellink) is the leading bio convergence company in the world. Cellink continues to operate as a wholly owned division of BICO. Organovo exclusively licensed early bioprinting work by Gabor Forgacs, its scientific founder, and Thomas Boland of Clemson, both bioprinting pioneers. After its founding, the company did early innovation in the 3D bioprinter space and obtained a further broad set of patents that provide foundational claims in the bioprinting space. In order to broaden the impact of the techno...

Benzinga | February 23, 2022

Organovo Welcomes New Sr. Vice President of Strategy and Business Development

SAN DIEGO , Feb. 18, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using 3D bioprinting technology, today announced the hiring of Curtis Tyree , PhD, as Sr.

Organovo Holdings | February 18, 2022

Organovo Holdings, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (“Organovo”), today announced that it has granted a stock option to purchase 50,000 shares of common stock to one new employee. The stock option was granted pursuant to the Organovo Holdings, Inc. 2021 Inducement Equity Incentive Plan and granted as an inducement material to the new employee entering into employment with Organovo in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option has an exercise

Yahoo | February 18, 2022

10 3D Printing Companies to Watch in 2022

In this article, we discuss the 10 3D printing companies to watch in 2022. If you want to skip our detailed analysis of these companies, go directly to 5 3D Printing Companies to Watch in 2022. Thought of as something straight from a science fiction novel up until a few decades ago, 3D printing has […]

Yahoo | February 12, 2022

Organovo Guides on Patent Portfolio and Successful IPR Defense of Two Patents

SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), today announced that two of its patents have withstood a patent challenge, and the company provided guidance on how it expects to leverage its strong patent portfolio. Organovo holds a powerful foundational patent portfolio in the 3D bioprinting space due to its licensing of pioneering work in the field and early innovations beyond that start. Organovo is focused today on bringing inflammatory bowel disease (IBD

Yahoo | February 2, 2022

15 Worst Stock Picks of Cathie Wood

In this article, we discuss the 15 worst stock picks of Cathie Wood. If you want to skip our detailed analysis of these stocks, go directly to the 5 Worst Stock Picks of Cathie Wood. Cathie Wood, the chief ARK Investment Management, is often hailed as the champion of “disruptive innovation” at the stock market. […]

Yahoo | January 21, 2022

Organovo Files Counterclaims In Patent Lawsuit Brought Against It by CellInk

SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), today released its first detailed response to the lawsuit Cellink (NASDAQ Stockholm: BICO) filed against it in Delaware court in 2021. At issue in this lawsuit is whether Cellink is infringing Organovo patents. Organovo, as one of the earliest and most prominent 3D bioprinting companies, has built a strong and foundational patent portfolio in the space. Organovo believes that Cellink, as a newer company with lim

Yahoo | January 10, 2022

Here's Why We're Not Too Worried About Organovo Holdings' (NASDAQ:ONVO) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Yahoo | December 30, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7831 seconds.